indicating that dose adjustment of MMF on the basis of therapeutic drug monitoring of MPA would be required.

Mycophenolic acid is a new treatment alternative that may be effective at early or late stages; controlled studies are pending. Rituximab may be effective in SSNS as rescue treatment for patients ...

Autologous stem cell transplant for patients with diffuse systemic sclerosis (SSc), without selecting for a particular ...

Summary: EC mycophenolate sodium is the EC salt form of mycophenolic acid (MPA), the active component of the pro-drug, mycophenolate mofetil. EC mycophenolate sodium was developed to reduce the ...